Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rhinitis Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Infections Nose Diseases Otorhinolaryngologic Diseases Respiratory Tract Diseases Respiratory Tract Infections Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Urticaria

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Outpatient men or women, age 12 years and above.
Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria

Exclusion criteria

Known hypersensitivity to Desloratadine.
Pregnancy or lactation

Treatment and study plan

desloratadine

Drug

Desloratadine 5 mg once daily

Other names: SCH 034117

Primary outcomes

Adverse Events

Time frame: Final Visit (Day 15)

Number of adverse events reported

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients

Acronym: Aerius

Important dates

Study start: 2005
Primary completion: 2007
Study completion: 2007
First posted: Jul 29, 2008
Registry last updated: Feb 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed